Trovagene Inc. (NASDAQ:TROV)’s share price traded up 3.1% during trading on Friday . The company traded as high as $5.27 and last traded at $5.24, with a volume of 242,486 shares traded. The stock had previously closed at $5.08.

A number of equities analysts recently commented on the company. Argus downgraded Trovagene from a “buy” rating to a “hold” rating in a report on Thursday, April 28th. Cantor Fitzgerald downgraded Trovagene from a “buy” rating to a “hold” rating and lowered their price target for the company from $9.00 to $5.00 in a report on Monday, April 25th. Leerink Swann downgraded Trovagene from an “outperform” rating to a “market perform” rating in a report on Monday, April 25th. Zacks Investment Research upgraded Trovagene from a “sell” rating to a “hold” rating in a report on Wednesday, July 13th. Finally, Piper Jaffray Cos. reiterated a “hold” rating and set a $5.00 price target (down previously from $8.00) on shares of Trovagene in a report on Thursday, May 12th. Seven investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Trovagene has an average rating of “Hold” and a consensus price target of $6.96.

The firm’s market capitalization is $150.50 million. The firm’s 50 day moving average is $4.75 and its 200-day moving average is $4.76.

Trovagene (NASDAQ:TROV) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by $0.07. Equities analysts anticipate that Trovagene Inc. will post ($1.30) EPS for the current fiscal year.

Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.